An observational study in Prostate Cancer (Adenocarcinoma), sponsored by Jules Bordet Institute. Recruiting at 1 site in Belgium. Open to male participants. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Jules Bordet Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Prostatic Neoplasms with a site in Belgium — 42 open to participants now, 77 under way, 33 of them phase 3. Prostatic Neoplasms · Belgium.
Among the 236 studies in Prostatic Neoplasms with a site in Belgium, this one is the 23rd largest by planned enrollment of the 27 observational ones that give a count, is one of 9 that started in 2026, is one of 27 observational ones, reaches primary completion later than 50 of the 76 other live ones, and was the 231st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →42 of the 236 studies in Prostatic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Australia and 21 more countries
Ages 18+ · Men only
BioNTech SE · Sites in Belgium, United States, Australia and 7 more countries
Ages 18+ · Men only
Bayer · Sites in Belgium, Finland, France and 13 more countries
Ages 18+ · Men only
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 18+ · Men only
Amgen · Sites in Belgium, United States, Australia and 15 more countries
Ages 18+ · Men only
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 59 · Phase 3 102 · Phase 4 6
First in 1992; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 283 across the 206 interventional studies, 805 across the 27 observational. Of the 152 that completed or were terminated, 78 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 236 have an industry lead sponsor. The 10 most frequent:
Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
Jules Bordet Institute has 5 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Prostatic Neoplasms with a site in Belgium that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT05352178Phase 3Universitaire Ziekenhuizen KU LeuvenMetastasis-directed Therapy for Oligorecurrent Prostate Cancer | 2027-04-25 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 236 studies in Prostatic Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A substantial proportion of patients with mCRPC do not respond to 177Lu-PSMA-RLT. The PSA response to Lu-PSMA was observed in nearly 46% of patients included in VISION trial and 66% in LuPSMA trial (4,5). The response to treatment can be evaluated after two cycles using the PSA or PSMA PET/CT scan. Gafita et al. Data have shown that PSA and PSMA perform equally in assessing response to 177Lu-PSMA treatment, and their changes after two cycles are related to patient survival. After two cycles, patients with no PSA or PSMA response had worse outcomes than those with partial response or stable disease . That means PSA and PSMA changes after two cycles can be used as a surrogate of patient outcome. However, the explanation of disease resistance to 177Lu-PSMA-RLT is not yet fully understood. Inappropriate dose administration might be one of the possible explanations. A dose-response relationship has been established in radiotherapy , making dosimetry a standard of care in conventional radiotherapy. In the radionuclide therapy settings, the dose-response relationship has been reported in a multi-center phase 2 trial on the selective internal radiotherapy in hepatocellular carcinoma. In this context, calculating the absorbed dose to tumour lesions could be an excellent method to individualize radionuclide therapy to achieve a maximal response to treatment. If dosimetry calculations could predict which patients would ultimately respond or not respond to treatment, administered dose and number of 177Lu-PSMA-RLT cycles could be adapted early during the treatment course. In this context, our study aims to analyze if absorbed tumour dose obtained by dosimetry calculations could be used as a biomarker to predict non-response to treatment early after one cycle, as the first step towards treatment dose adaptation of a personalized radionuclide treatment approach.
Progressive metastatic prostate cancer
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient-based response defined as a decline of serum PSA ≥50% at 12th weeks (after 2 cycles) after treatment initiation.
Time frame: 12th week after treatment initiation
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Dec 2027, 22 months later.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 22 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.